Total amount: € 0,00
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236
Online ISSN 1827-1669
Arrigo FRUSCALZO 1, 2, Ambrogio P. LONDERO 3, Serena BERTOZZI 4, Ralf J. LELLÉ 2
1 Obstetrics and Gynecology, St. Franziskus Hospital Münster, Germany; 2 Obstetrics and Gynecology University of Münster, Münster, Germany; 3 Unit of Obstetrics and Gynecology, S. Polo Hospital, Monfalcone, Italy; 4 Surgical Oncology Department, IRCSS CRO, Aviano, Italy
Two vaccines focused on the prevention of HPV-related diseases have been introduced in the last decade, the quadrivalent vaccine Gardasil® and the bivalent vaccine Cervarix®. They are targeted to prevent precancerous and cancerous lesions not only of the cervix, but also of the vulva, vagina, anal and head-neck region. Furthermore, the protection of the quadrivalent vaccine Gardasil includes also genital warts and recurrent respiratory Papillomatosis, two benign conditions with high socio-economic impact. Although their efficacy in reducing the burden of HPV-related pathologies has been already documented, second-generation HPV vaccines are being developed in order to overcome major limitations, above all the cost of production, distribution and acceptance, thus promoting an easier access to vaccination, especially in developing countries. Recently a new multivalent VLP vaccine active against nine HPV subtypes, called Gardasil 9® (Merck & Co., Inc., Whitehouse Station, NJ, USA), has been approved, showing promising preliminary results. In this article, we outline the strategies adopted for second-generation HPV vaccine engineering, the latest HPV vaccines available at this time, as well as those currently in development.